Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer [RNAseq]

ABSTRACT: The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer [RNAseq]

PROVIDER: PRJNA871278 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer [Methylation array]

Project description:Less than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSC) survive more than five years post-diagnosis but those who have an exceptionally long survival could provide new insights into tumor biology and therapeutic approaches. We analyzed 60 patients with advanced-stage, HGSC who survived more than 10 years after diagnosis using whole-genome sequencing, transcriptome, and methylome profiling of their primary tumor samples, comparing this data to 66 short- or moderate-term survivors. Tumors of long-term survivors were more likely to have multiple alterations in genes associated with DNA repair, and more frequent somatic variants resulting in an increased predicted neoantigen load. Patients clustered into survival groups based on genomic and immune cell signatures, including three subsets of patients with BRCA1 alterations with distinctly different outcomes. Specific combinations of germline and somatic gene alterations, tumor cell phenotypes, and differential immune responses appear to contribute to long-term survival in HGSC. Methylation profiling was done on 58 high grade serous ovarian cancer samples, 53 of which were primary tumors and and 5 were relapse tumors. 73 primary tumors from GSE65820 were also used as part of the cohort.

2022-08-26 | GSE211686 | GEO

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer [RNAseq]

2022-08-26 | GSE211669 | GEO

Molecular Analysis of Short- Versus Long-term Survivors of High-Grade Serous Ovarian Carcinoma

Project description:Molecular Analysis of Short- Versus Long-term Survivors of High-Grade Serous Ovarian Carcinoma

| PRJNA868089 | ENA

Molecular Analysis of Short- Versus Long-term Survivors of High-Grade Serous Ovarian Carcinoma

Project description:Molecular Analysis of Short- Versus Long-term Survivors of High-Grade Serous Ovarian Carcinoma

| PRJNA868088 | ENA

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

Project description:The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

| PRJNA871356 | ENA

LncRNA and mRNA expression profiles in High-grade serous ovarian cancer, Low-grade serous ovarian cancer and Normal fallopian tube

Project description:Ovarian cancer is the most lethal gynecologic cancer. High-grade serous ovarian carcinoma (HGSOC) is the most common histologic subtype, accounting for three quarters of ovarian cancer. To clarify the changes of gene expression in serous ovarian cancer, we performed lncRNA and mRNA microarrays to identify differentially expressed lncRNAs and mRNAs in High-grade and Low-grade serous ovarian carcinoma compared with Normal fallopian tube.

2020-02-12 | GSE135886 | GEO

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer [Methylation array]

Project description:The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer [Methylation array]

| PRJNA871353 | ENA

FXYD5 (dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer

Project description:High-grade serous ovarian carcinoma (HGSOC) is generally associated with a very dismal prognosis. Nevertheless, patients with similar clinicopathological characteristics can have markedly different clinical outcomes. Our aim was the identification of novel molecular determinants influencing survival. Gene expression profiles of 12 HGSOC long-term and 27 short-term survivors (training set) were generated by microarray, and a prognostic signature was identified and further evaluated on an independent extensive HGSOC dataset through a meta-analysis approach.

2019-11-14 | GSE131978 | GEO

miRNA profiling in high-grade serous ovarian carcinoma

Project description:In this study, we performed miRNA profiles analysis of high-grade serous ovarian carcinoma compared to normal fallopian tube fimbria using microarray (Exiqon, Denmark) to evaluate their potential role in the pathogenesis of uterine leiomyoma. miRNA profiling analysis of the 10 samples including 5 high-grade serous ovarian carcinomas and 5 normal fallopian tube fimbria.

2014-11-14 | E-GEOD-61485 | biostudies-arrayexpress

Genomic analysis of low-grade serous ovarian carcinomas [IL610Q]

Project description:Low-grade serous ovarian carcinomas are typically Ras-pathway mutated, TP53 wild-type, have limited chromosomal aberration, and are frequently associated with borderline tumors. By contrast, high-grade serous ovarian carcinoma lack Ras-pathway mutations, are invariably TP53 mutated, show widespread genomic change, and are commonly BRCA-pathway disrupted. We sought to identify differences in genomic copy number changes between co-existing borderline and invasive components of serous carcinoma. Paired co-existing borderline and invasive tumor components of ovarian serous carcinoma were sampled and profiled from tumors from 7 patients

2014-10-01 | E-GEOD-57279 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data